WO2006101740A3 - Compounds having activity in correcting mutant-cftr processing and uses thereof - Google Patents

Compounds having activity in correcting mutant-cftr processing and uses thereof

Info

Publication number
WO2006101740A3
WO2006101740A3 PCT/US2006/008267 US2006008267W WO2006101740A3 WO 2006101740 A3 WO2006101740 A3 WO 2006101740A3 US 2006008267 W US2006008267 W US 2006008267W WO 2006101740 A3 WO2006101740 A3 WO 2006101740A3
Authority
WO
WIPO (PCT)
Prior art keywords
containing compounds
compounds
activity
mutant
cftr
Prior art date
Application number
PCT/US2006/008267
Other languages
French (fr)
Other versions
WO2006101740A2 (en
Inventor
Alan Verkman
Nicoletta Pedemonte
Luis J V Galietta
Original Assignee
Univ California
Alan Verkman
Nicoletta Pedemonte
Luis J V Galietta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Alan Verkman, Nicoletta Pedemonte, Luis J V Galietta filed Critical Univ California
Priority to MX2007011512A priority Critical patent/MX2007011512A/en
Priority to US11/908,591 priority patent/US8143295B2/en
Priority to AU2006227833A priority patent/AU2006227833A1/en
Priority to EP06737438A priority patent/EP1863522A4/en
Priority to JP2008501913A priority patent/JP2008538107A/en
Priority to CA002600869A priority patent/CA2600869A1/en
Priority to BRPI0608453-2A priority patent/BRPI0608453A2/en
Publication of WO2006101740A2 publication Critical patent/WO2006101740A2/en
Priority to IL185999A priority patent/IL185999A0/en
Publication of WO2006101740A3 publication Critical patent/WO2006101740A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ΔF508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinylaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquinoline-containing compounds of the invention, or an analog or derivative thereof.
PCT/US2006/008267 2005-03-18 2006-03-08 Compounds having activity in correcting mutant-cftr processing and uses thereof WO2006101740A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2007011512A MX2007011512A (en) 2005-03-18 2006-03-08 Compounds having activity in correcting mutant-cftr processing and uses thereof.
US11/908,591 US8143295B2 (en) 2005-03-18 2006-03-08 Compounds having activity in correcting mutant-CFTR processing and uses thereof
AU2006227833A AU2006227833A1 (en) 2005-03-18 2006-03-08 Compounds having activity in correcting mutant-CFTR processing and uses thereof
EP06737438A EP1863522A4 (en) 2005-03-18 2006-03-08 Compounds having activity in correcting mutant-cftr processing and uses thereof
JP2008501913A JP2008538107A (en) 2005-03-18 2006-03-08 Compounds having activity in correcting mutant CFTR processing and uses thereof
CA002600869A CA2600869A1 (en) 2005-03-18 2006-03-08 Compounds having activity in correcting mutant-cftr processing and uses thereof
BRPI0608453-2A BRPI0608453A2 (en) 2005-03-18 2006-03-08 compounds having activity in the correction of mutant cftr processing and uses of these
IL185999A IL185999A0 (en) 2005-03-18 2007-09-17 Compounds having activity in correcting mutant-cftr processing and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66350105P 2005-03-18 2005-03-18
US60/663,501 2005-03-18

Publications (2)

Publication Number Publication Date
WO2006101740A2 WO2006101740A2 (en) 2006-09-28
WO2006101740A3 true WO2006101740A3 (en) 2009-06-04

Family

ID=37024308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/008267 WO2006101740A2 (en) 2005-03-18 2006-03-08 Compounds having activity in correcting mutant-cftr processing and uses thereof

Country Status (12)

Country Link
US (1) US8143295B2 (en)
EP (1) EP1863522A4 (en)
JP (1) JP2008538107A (en)
KR (1) KR20070114820A (en)
CN (1) CN101605543A (en)
AU (1) AU2006227833A1 (en)
BR (1) BRPI0608453A2 (en)
CA (1) CA2600869A1 (en)
IL (1) IL185999A0 (en)
MX (1) MX2007011512A (en)
RU (1) RU2007138584A (en)
WO (1) WO2006101740A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952050B2 (en) 2006-04-07 2015-02-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
PL1773816T3 (en) 2004-06-24 2015-06-30 Vertex Pharma Modulators of ATP-binding cassette transporters
CA2635214A1 (en) * 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
PL2007756T3 (en) 2006-04-07 2016-01-29 Vertex Pharma Modulators of atp-binding cassette transporters
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CN101096363B (en) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-three-substituted thiazole compound, preparation method, medicament composition and pharmacy use thereof
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8283351B2 (en) 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
CN101687851B (en) 2007-05-07 2013-02-27 诺瓦提斯公司 Organic compounds
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
NZ585236A (en) 2007-10-09 2012-03-30 Merck Patent Gmbh Pyridine derivatives useful as glucokinase activators
WO2009051909A1 (en) * 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
US8507524B2 (en) 2007-11-16 2013-08-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette-transporters
BRPI0821039B8 (en) 2007-12-07 2021-05-25 Vertex Pharma solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, process for their preparation , pharmaceutical compositions comprising the same and uses
AU2008334629B2 (en) 2007-12-10 2012-04-12 Novartis Ag Organic compounds
AU2009231993B2 (en) 2008-03-31 2013-10-10 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
US8236808B2 (en) 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
US20120058918A1 (en) * 2009-02-02 2012-03-08 Chromocell Corporation Cell lines expressing cftr and methods of using them
EP2408750B1 (en) 2009-03-20 2015-08-26 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
JP2013508414A (en) 2009-10-22 2013-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド Compositions for the treatment of cystic fibrosis and other chronic diseases
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN109081804B (en) 2010-03-25 2021-12-10 弗特克斯药品有限公司 Solid forms of cyclopropanecarboxamides
JP2013523833A (en) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 3- (6- (1- (2,2-difluorobenzo [D] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid pharmaceutical composition and Its administration
WO2011127290A2 (en) 2010-04-07 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
AU2011293658B2 (en) 2010-08-23 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
EP2826771B1 (en) 2010-09-14 2018-12-12 Instytut Biochemii I Biofizyki Polskiej Akademii Nauk Compounds as modulators of a mutant CFTR protein and their use for treating diseases associated with CFTR protein malfunction
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
CA2754237A1 (en) 2011-05-27 2012-11-27 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
WO2012166654A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Cyanoquinoline compounds having activity in correcting mutant-cftr processing and increasing ion transport and uses thereof
US8883473B2 (en) 2011-06-29 2014-11-11 Janssen Pharmaceutica N.V. Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases
WO2013003358A2 (en) 2011-06-29 2013-01-03 Janssen Pharmaceutica Nv Methods for designing, selecting and/or optimizing allosteric processing inhibitors for matrix metalloproteinases
CA2840202A1 (en) 2011-06-29 2013-01-03 Janssen Pharmaceutica Nv Crystal structure of the pro form of a matrix metalloproteinase and an allosteric processing inhibitor
CA2852991C (en) 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CA3128556A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2014014841A1 (en) 2012-07-16 2014-01-23 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
HRP20181740T4 (en) 2012-11-02 2024-01-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
ITMI20122065A1 (en) 2012-12-03 2014-06-04 Univ Padova USE OF CFTR CORRECTORS IN THE TREATMENT OF STRUCTURAL MUSCLE PATHOLOGIES
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
GB201405991D0 (en) * 2014-04-03 2014-05-21 Cambridge Entpr Ltd Novel compounds
SI3424534T1 (en) 2014-04-15 2021-08-31 Vertex Pharmaceutical Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
RU2020134082A (en) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед MODULATORS OF THE TRANSMEMBRANE CONDUCTIVITY REGULATOR IN FLUISCIDOSIS
MX370450B (en) 2014-10-07 2019-12-13 Vertex Pharma Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator.
CA2969587A1 (en) 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
US10828288B2 (en) 2015-01-27 2020-11-10 Rutgers, The State University Of New Jersey Hydrazone derivatives for the treatment of cancer
US10729671B2 (en) 2015-01-27 2020-08-04 Rutgers, The State University Of New Jersey Zinc complexes of hydrazones and (thio)semicarbazones and their use for the treatment of cancer
WO2016123246A1 (en) 2015-01-27 2016-08-04 Rutgers, The State University Of New Jersey (thio, oxo and seleno) semicarbazone complexes with zinc and their use for treating cancer
WO2016123242A1 (en) 2015-01-27 2016-08-04 Rutgers, The State University Of New Jersey (thio)semicarbazone derivatives and their use for treating cancer
BR112017016205A2 (en) 2015-02-09 2018-03-27 Romani Luigina thymosin alpha 1 for use in the treatment of cystic fibrosis
ITUB20153714A1 (en) * 2015-09-18 2017-03-18 Luigina Romani Thymosine alfa 1 for use in the treatment of cystic fibrosis.
WO2017060880A1 (en) * 2015-10-09 2017-04-13 AbbVie S.à.r.l. Potentiator-corrector combinations useful in the treatment of cystic fibrosis
CA3088229A1 (en) 2018-01-11 2019-07-18 Genethon Combination treatment of sarcoglycanopathies
KR20210088532A (en) 2018-09-09 2021-07-14 카나트파마 아게 Use of CFT modulators to treat cerebrovascular conditions
KR102399037B1 (en) * 2020-01-06 2022-05-17 성균관대학교산학협력단 Novel Production Method for Aminated Azine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501750A (en) * 1981-01-13 1985-02-26 Mitsui Toatsu Kaguku Kabushiki Kaisha Thiazole compounds, a process for preparing same and a pharmaceutical composition containing the thiazole compounds
EP0519449A1 (en) * 1991-06-21 1992-12-23 Boehringer Mannheim Italia S.P.A. 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract
US6770663B2 (en) * 2000-12-29 2004-08-03 Alteon, Inc. Method for treating fibrotic diseases or other indications utilizing thiazole, oxazole and imidazole compounds
WO2004110352A2 (en) * 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS649935A (en) 1987-06-30 1989-01-13 Kyowa Hakko Kogyo Kk Remedy for hepatopathy
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
HN2002000156A (en) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals BENZAMIDE THIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT THE PROLIFERATION OF CELLS AND METHODS FOR THEIR USE.
SE0201837D0 (en) 2002-06-14 2002-06-14 Astrazeneca Ab Chemical compounds
US7329682B2 (en) * 2003-04-03 2008-02-12 Ewha University-Industry Collaboration Foundation Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
WO2004098510A2 (en) 2003-04-30 2004-11-18 Beth Israel Deaconess Medical Center Cystic fibrosis therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501750A (en) * 1981-01-13 1985-02-26 Mitsui Toatsu Kaguku Kabushiki Kaisha Thiazole compounds, a process for preparing same and a pharmaceutical composition containing the thiazole compounds
EP0519449A1 (en) * 1991-06-21 1992-12-23 Boehringer Mannheim Italia S.P.A. 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract
US6770663B2 (en) * 2000-12-29 2004-08-03 Alteon, Inc. Method for treating fibrotic diseases or other indications utilizing thiazole, oxazole and imidazole compounds
WO2004110352A2 (en) * 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOYAKA. E. C. ET AL.: "Rescuing Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Processing Mutants by Transcomplementation", PNAS, vol. 101, no. 21, May 2004 (2004-05-01), pages 8221 - 8226, XP003024143 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952050B2 (en) 2006-04-07 2015-02-10 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters

Also Published As

Publication number Publication date
US20080318984A1 (en) 2008-12-25
AU2006227833A1 (en) 2006-09-28
BRPI0608453A2 (en) 2009-12-29
CA2600869A1 (en) 2006-09-28
EP1863522A4 (en) 2010-11-10
WO2006101740A2 (en) 2006-09-28
US8143295B2 (en) 2012-03-27
JP2008538107A (en) 2008-10-09
CN101605543A (en) 2009-12-16
KR20070114820A (en) 2007-12-04
MX2007011512A (en) 2007-12-07
EP1863522A2 (en) 2007-12-12
IL185999A0 (en) 2008-08-07
RU2007138584A (en) 2009-04-27

Similar Documents

Publication Publication Date Title
WO2006101740A3 (en) Compounds having activity in correcting mutant-cftr processing and uses thereof
WO2005120497A3 (en) Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2006127588A3 (en) Modulators of atp-binding cassette transporters
WO2007117715A3 (en) Modulators of atp-binding cassette transporters
WO2005021022A3 (en) Stable formulations of peptides
WO2004110352A3 (en) Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2007043048A3 (en) Self-assembled fmoc-ff hydrogels
WO2007075525A3 (en) Combination of an iap-inhibitor and a taxane7
WO2007044560A3 (en) Modulators of atp-binding cassette transporters
EP1831240B8 (en) 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones and pharmaceutical preparations comprising the same
WO2010053471A8 (en) Modulators of atp-binding cassette transporters
WO2010054138A3 (en) Modulators of atp-binding cassette transporters
WO2007047253A3 (en) Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
WO2006052860A3 (en) Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2007057714A3 (en) Pharmaceutical compositions comprising methotrexate
WO2006021001A3 (en) Amphiphilic polynorbornene derivatives and methods of using the same
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
EP3915991A4 (en) Pyrrolopyrimidine derivative, and pharmaceutical composition for preventing or treating protein kinase-related disease comprising same as active ingredient
WO2006091836A8 (en) Formulations of ladostigil tartrate
CA2530613A1 (en) Rasgap derived peptide for selectively killing cancer cells
WO2007044437A3 (en) Octanol formulations and methods of treatment using the same
WO2006047728A3 (en) Bmp gene and fusion protein
EP1586307A3 (en) Cosmetic or pharmaceutical compositions containing preserved taurine
WO2005071067A3 (en) Non-animal origin stabilizers and processes for producing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680015035.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2600869

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006227833

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008501913

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 185999

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/011512

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006227833

Country of ref document: AU

Date of ref document: 20060308

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006737438

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 7887/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007138584

Country of ref document: RU

Ref document number: 1020077024001

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 11908591

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0608453

Country of ref document: BR

Kind code of ref document: A2